PLX (STOCKS)
Protalix BioTherapeutics, Inc. Common Stock
$2.060000
-0.030000 (-1.44%)
Prev close: $2.090000
Company Information
- Exchange
- XASE
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Dror Bashan
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $166.38M
- Employees
- 213
- P/E (TTM)
- 11.40
- P/B (TTM)
- 2.50
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
1
Strong Buy
3
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$0.22 | $-0.01 | +0.2301 | +2,278.22% |
|
Mar 2025 (Q4)
|
$-0.07 | $0.01 | -0.0751 | -1,472.55% |
|
Sep 2025 (Q3)
|
$0.03 | $0.06 | -0.0256 | -46.04% |
|
Jun 2025 (Q2)
|
$0.00 | $0.03 | -0.0303 | -100.00% |
Financial Statements
| Revenues | $76.38M |
| Benefits Costs and Expenses | $57.12M |
| Cost Of Revenue | $22.94M |
| Costs And Expenses | $57.12M |
| Gross Profit | $53.44M |
| Nonoperating Income/Loss | -$526.00K |
| Operating Expenses | $33.65M |
| Selling, General, and Administrative Expenses | $12.13M |
| Research and Development | $21.52M |
| Operating Income/Loss | $19.79M |
| Income/Loss From Continuing Operations After Tax | $15.33M |
| Income/Loss From Continuing Operations Before Tax | $19.27M |
| Income Tax Expense/Benefit | $3.93M |
| Income Tax Expense/Benefit, Deferred | $524.00K |
| Net Income/Loss | $15.33M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $15.33M |
| Net Income/Loss Available To Common Stockholders, Basic | $15.33M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.20 |
| Diluted Earnings Per Share | $0.19 |
| Basic Average Shares | 81,783,146 |
| Diluted Average Shares | 84,982,850 |
| Assets | $102.34M |
| Current Assets | $86.36M |
| Inventory | $30.47M |
| Other Current Assets | $55.88M |
| Noncurrent Assets | $15.98M |
| Fixed Assets | $5.15M |
| Other Non-current Assets | $10.83M |
| Liabilities | $35.11M |
| Current Liabilities | $27.39M |
| Wages | $3.71M |
| Other Current Liabilities | $23.68M |
| Noncurrent Liabilities | $7.72M |
| Equity | $67.23M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $67.23M |
| Liabilities And Equity | $102.34M |
| Net Cash Flow From Operating Activities | $15.09M |
| Net Cash Flow From Operating Activities, Continuing | $15.09M |
| Net Cash Flow From Investing Activities | $2.17M |
| Net Cash Flow From Investing Activities, Continuing | $2.17M |
| Net Cash Flow From Financing Activities | $4.40M |
| Net Cash Flow From Financing Activities, Continuing | $4.40M |
| Net Cash Flow | $21.66M |
| Net Cash Flow, Continuing | $21.66M |
| Comprehensive Income/Loss | $15.33M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $15.33M |
| Other Comprehensive Income/Loss | $0.00 |